ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Primary Sclerosing Cholangitis (PSC) Market Research Report 2025
Published Date: April 2025
|
Report Code: QYRE-Auto-38K12709
Home | Market Reports | Health| Nursing
Global Primary Sclerosing Cholangitis PSC Market Research Report 2023
BUY CHAPTERS

Global Primary Sclerosing Cholangitis (PSC) Market Research Report 2025

Code: QYRE-Auto-38K12709
Report
April 2025
Pages:91
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Acorda Therapeutics
Gilead Sciences
NGM Biopharmaceuticals
Intercept Pharmaceuticals
Dr. Falk Pharma
Allergan plc
Shire Plc
DURECT Corporation
Conatus Pharmaceuticals
Sirnaomics
Glenmark
Impax Laboratories
Mylan NV
Teva Pharmaceuticals
Daewoong Pharmaceutical
Mitsubishi Tanabe Pharma
Lannett
Shenzhen HighTide Biopharmaceutical

Primary Sclerosing Cholangitis (PSC) Market

The global market for Primary Sclerosing Cholangitis (PSC) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease that primarily affects the bile ducts. The term "sclerosing" refers to the scarring and narrowing (stricturing) of the bile ducts, which impedes the flow of bile from the liver to the small intestine. PSC is characterized by inflammation and fibrosis of the bile ducts, leading to a range of liver and digestive issues.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
This report aims to provide a comprehensive presentation of the global market for Primary Sclerosing Cholangitis (PSC), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Sclerosing Cholangitis (PSC).
The Primary Sclerosing Cholangitis (PSC) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Primary Sclerosing Cholangitis (PSC) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Primary Sclerosing Cholangitis (PSC) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Primary Sclerosing Cholangitis (PSC) Market Report

Report Metric Details
Report Name Primary Sclerosing Cholangitis (PSC) Market
Segment by Type
Segment by Application
  • Hospital
  • Clinics
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Acorda Therapeutics, Gilead Sciences, NGM Biopharmaceuticals, Intercept Pharmaceuticals, Dr. Falk Pharma, Allergan, Shire, Durect Corporation, Conatus Pharmaceuticals, Sirnaomics, Shenzhen HighTide Biopharmaceutical, Glenmark, Impax Laboratories, Mylan, Teva Pharmaceuticals, Daewoong Pharmaceutical, Mitsubishi Tanabe Pharma, Lannett
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Primary Sclerosing Cholangitis (PSC) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Primary Sclerosing Cholangitis (PSC) Market report?

Ans: The main players in the Primary Sclerosing Cholangitis (PSC) Market are Acorda Therapeutics, Gilead Sciences, NGM Biopharmaceuticals, Intercept Pharmaceuticals, Dr. Falk Pharma, Allergan, Shire, Durect Corporation, Conatus Pharmaceuticals, Sirnaomics, Shenzhen HighTide Biopharmaceutical, Glenmark, Impax Laboratories, Mylan, Teva Pharmaceuticals, Daewoong Pharmaceutical, Mitsubishi Tanabe Pharma, Lannett

What are the Application segmentation covered in the Primary Sclerosing Cholangitis (PSC) Market report?

Ans: The Applications covered in the Primary Sclerosing Cholangitis (PSC) Market report are Hospital, Clinics, Others

What are the Type segmentation covered in the Primary Sclerosing Cholangitis (PSC) Market report?

Ans: The Types covered in the Primary Sclerosing Cholangitis (PSC) Market report are Medical Treatement, Liver Transplantation, Others

Recommended Reports

Liver Disease Markets

Biliary & Digestive

Autoimmune Disorders

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Medical Treatement
1.2.3 Liver Transplantation
1.2.4 Others
1.3 Market by Application
1.3.1 Global Primary Sclerosing Cholangitis (PSC) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Primary Sclerosing Cholangitis (PSC) Market Perspective (2020-2031)
2.2 Global Primary Sclerosing Cholangitis (PSC) Growth Trends by Region
2.2.1 Global Primary Sclerosing Cholangitis (PSC) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Primary Sclerosing Cholangitis (PSC) Historic Market Size by Region (2020-2025)
2.2.3 Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Region (2026-2031)
2.3 Primary Sclerosing Cholangitis (PSC) Market Dynamics
2.3.1 Primary Sclerosing Cholangitis (PSC) Industry Trends
2.3.2 Primary Sclerosing Cholangitis (PSC) Market Drivers
2.3.3 Primary Sclerosing Cholangitis (PSC) Market Challenges
2.3.4 Primary Sclerosing Cholangitis (PSC) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Primary Sclerosing Cholangitis (PSC) Players by Revenue
3.1.1 Global Top Primary Sclerosing Cholangitis (PSC) Players by Revenue (2020-2025)
3.1.2 Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Players (2020-2025)
3.2 Global Primary Sclerosing Cholangitis (PSC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Primary Sclerosing Cholangitis (PSC) Revenue
3.4 Global Primary Sclerosing Cholangitis (PSC) Market Concentration Ratio
3.4.1 Global Primary Sclerosing Cholangitis (PSC) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Sclerosing Cholangitis (PSC) Revenue in 2024
3.5 Global Key Players of Primary Sclerosing Cholangitis (PSC) Head office and Area Served
3.6 Global Key Players of Primary Sclerosing Cholangitis (PSC), Product and Application
3.7 Global Key Players of Primary Sclerosing Cholangitis (PSC), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Sclerosing Cholangitis (PSC) Breakdown Data by Type
4.1 Global Primary Sclerosing Cholangitis (PSC) Historic Market Size by Type (2020-2025)
4.2 Global Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Type (2026-2031)
5 Primary Sclerosing Cholangitis (PSC) Breakdown Data by Application
5.1 Global Primary Sclerosing Cholangitis (PSC) Historic Market Size by Application (2020-2025)
5.2 Global Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Primary Sclerosing Cholangitis (PSC) Market Size (2020-2031)
6.2 North America Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2020-2025)
6.4 North America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Primary Sclerosing Cholangitis (PSC) Market Size (2020-2031)
7.2 Europe Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2020-2025)
7.4 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size (2020-2031)
8.2 Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size by Region (2020-2025)
8.4 Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Primary Sclerosing Cholangitis (PSC) Market Size (2020-2031)
9.2 Latin America Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2020-2025)
9.4 Latin America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size (2020-2031)
10.2 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Country (2020-2025)
10.4 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Acorda Therapeutics
11.1.1 Acorda Therapeutics Company Details
11.1.2 Acorda Therapeutics Business Overview
11.1.3 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Introduction
11.1.4 Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.1.5 Acorda Therapeutics Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Details
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Introduction
11.2.4 Gilead Sciences Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.2.5 Gilead Sciences Recent Development
11.3 NGM Biopharmaceuticals
11.3.1 NGM Biopharmaceuticals Company Details
11.3.2 NGM Biopharmaceuticals Business Overview
11.3.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Introduction
11.3.4 NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.3.5 NGM Biopharmaceuticals Recent Development
11.4 Intercept Pharmaceuticals
11.4.1 Intercept Pharmaceuticals Company Details
11.4.2 Intercept Pharmaceuticals Business Overview
11.4.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Introduction
11.4.4 Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.4.5 Intercept Pharmaceuticals Recent Development
11.5 Dr. Falk Pharma
11.5.1 Dr. Falk Pharma Company Details
11.5.2 Dr. Falk Pharma Business Overview
11.5.3 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Introduction
11.5.4 Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.5.5 Dr. Falk Pharma Recent Development
11.6 Allergan
11.6.1 Allergan Company Details
11.6.2 Allergan Business Overview
11.6.3 Allergan Primary Sclerosing Cholangitis (PSC) Introduction
11.6.4 Allergan Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.6.5 Allergan Recent Development
11.7 Shire
11.7.1 Shire Company Details
11.7.2 Shire Business Overview
11.7.3 Shire Primary Sclerosing Cholangitis (PSC) Introduction
11.7.4 Shire Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.7.5 Shire Recent Development
11.8 Durect Corporation
11.8.1 Durect Corporation Company Details
11.8.2 Durect Corporation Business Overview
11.8.3 Durect Corporation Primary Sclerosing Cholangitis (PSC) Introduction
11.8.4 Durect Corporation Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.8.5 Durect Corporation Recent Development
11.9 Conatus Pharmaceuticals
11.9.1 Conatus Pharmaceuticals Company Details
11.9.2 Conatus Pharmaceuticals Business Overview
11.9.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Introduction
11.9.4 Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.9.5 Conatus Pharmaceuticals Recent Development
11.10 Sirnaomics
11.10.1 Sirnaomics Company Details
11.10.2 Sirnaomics Business Overview
11.10.3 Sirnaomics Primary Sclerosing Cholangitis (PSC) Introduction
11.10.4 Sirnaomics Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.10.5 Sirnaomics Recent Development
11.11 Shenzhen HighTide Biopharmaceutical
11.11.1 Shenzhen HighTide Biopharmaceutical Company Details
11.11.2 Shenzhen HighTide Biopharmaceutical Business Overview
11.11.3 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Introduction
11.11.4 Shenzhen HighTide Biopharmaceutical Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.11.5 Shenzhen HighTide Biopharmaceutical Recent Development
11.12 Glenmark
11.12.1 Glenmark Company Details
11.12.2 Glenmark Business Overview
11.12.3 Glenmark Primary Sclerosing Cholangitis (PSC) Introduction
11.12.4 Glenmark Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.12.5 Glenmark Recent Development
11.13 Impax Laboratories
11.13.1 Impax Laboratories Company Details
11.13.2 Impax Laboratories Business Overview
11.13.3 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Introduction
11.13.4 Impax Laboratories Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.13.5 Impax Laboratories Recent Development
11.14 Mylan
11.14.1 Mylan Company Details
11.14.2 Mylan Business Overview
11.14.3 Mylan Primary Sclerosing Cholangitis (PSC) Introduction
11.14.4 Mylan Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.14.5 Mylan Recent Development
11.15 Teva Pharmaceuticals
11.15.1 Teva Pharmaceuticals Company Details
11.15.2 Teva Pharmaceuticals Business Overview
11.15.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Introduction
11.15.4 Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.15.5 Teva Pharmaceuticals Recent Development
11.16 Daewoong Pharmaceutical
11.16.1 Daewoong Pharmaceutical Company Details
11.16.2 Daewoong Pharmaceutical Business Overview
11.16.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Introduction
11.16.4 Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.16.5 Daewoong Pharmaceutical Recent Development
11.17 Mitsubishi Tanabe Pharma
11.17.1 Mitsubishi Tanabe Pharma Company Details
11.17.2 Mitsubishi Tanabe Pharma Business Overview
11.17.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Introduction
11.17.4 Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.17.5 Mitsubishi Tanabe Pharma Recent Development
11.18 Lannett
11.18.1 Lannett Company Details
11.18.2 Lannett Business Overview
11.18.3 Lannett Primary Sclerosing Cholangitis (PSC) Introduction
11.18.4 Lannett Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
11.18.5 Lannett Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Acorda Therapeutics
Gilead Sciences
NGM Biopharmaceuticals
Intercept Pharmaceuticals
Dr. Falk Pharma
Allergan plc
Shire Plc
DURECT Corporation
Conatus Pharmaceuticals
Sirnaomics
Glenmark
Impax Laboratories
Mylan NV
Teva Pharmaceuticals
Daewoong Pharmaceutical
Mitsubishi Tanabe Pharma
Lannett
Shenzhen HighTide Biopharmaceutical
List of Tables
 Table 1. Global Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Medical Treatement
 Table 3. Key Players of Liver Transplantation
 Table 4. Key Players of Others
 Table 5. Global Primary Sclerosing Cholangitis (PSC) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Primary Sclerosing Cholangitis (PSC) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Primary Sclerosing Cholangitis (PSC) Market Size by Region (2020-2025) & (US$ Million)
 Table 8. Global Primary Sclerosing Cholangitis (PSC) Market Share by Region (2020-2025)
 Table 9. Global Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 10. Global Primary Sclerosing Cholangitis (PSC) Market Share by Region (2026-2031)
 Table 11. Primary Sclerosing Cholangitis (PSC) Market Trends
 Table 12. Primary Sclerosing Cholangitis (PSC) Market Drivers
 Table 13. Primary Sclerosing Cholangitis (PSC) Market Challenges
 Table 14. Primary Sclerosing Cholangitis (PSC) Market Restraints
 Table 15. Global Primary Sclerosing Cholangitis (PSC) Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global Primary Sclerosing Cholangitis (PSC) Market Share by Players (2020-2025)
 Table 17. Global Top Primary Sclerosing Cholangitis (PSC) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis (PSC) as of 2024)
 Table 18. Ranking of Global Top Primary Sclerosing Cholangitis (PSC) Companies by Revenue (US$ Million) in 2024
 Table 19. Global 5 Largest Players Market Share by Primary Sclerosing Cholangitis (PSC) Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of Primary Sclerosing Cholangitis (PSC), Headquarters and Area Served
 Table 21. Global Key Players of Primary Sclerosing Cholangitis (PSC), Product and Application
 Table 22. Global Key Players of Primary Sclerosing Cholangitis (PSC), Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Primary Sclerosing Cholangitis (PSC) Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Type (2020-2025)
 Table 26. Global Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Type (2026-2031)
 Table 28. Global Primary Sclerosing Cholangitis (PSC) Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Application (2020-2025)
 Table 30. Global Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Application (2026-2031)
 Table 32. North America Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 33. North America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2020-2025) & (US$ Million)
 Table 34. North America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2026-2031) & (US$ Million)
 Table 35. Europe Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2020-2025) & (US$ Million)
 Table 37. Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size by Region (2020-2025) & (US$ Million)
 Table 40. Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size by Region (2026-2031) & (US$ Million)
 Table 41. Latin America Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Latin America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2020-2025) & (US$ Million)
 Table 43. Latin America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2026-2031) & (US$ Million)
 Table 44. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Acorda Therapeutics Company Details
 Table 48. Acorda Therapeutics Business Overview
 Table 49. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Product
 Table 50. Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 51. Acorda Therapeutics Recent Development
 Table 52. Gilead Sciences Company Details
 Table 53. Gilead Sciences Business Overview
 Table 54. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Product
 Table 55. Gilead Sciences Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 56. Gilead Sciences Recent Development
 Table 57. NGM Biopharmaceuticals Company Details
 Table 58. NGM Biopharmaceuticals Business Overview
 Table 59. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Product
 Table 60. NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 61. NGM Biopharmaceuticals Recent Development
 Table 62. Intercept Pharmaceuticals Company Details
 Table 63. Intercept Pharmaceuticals Business Overview
 Table 64. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product
 Table 65. Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 66. Intercept Pharmaceuticals Recent Development
 Table 67. Dr. Falk Pharma Company Details
 Table 68. Dr. Falk Pharma Business Overview
 Table 69. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Product
 Table 70. Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 71. Dr. Falk Pharma Recent Development
 Table 72. Allergan Company Details
 Table 73. Allergan Business Overview
 Table 74. Allergan Primary Sclerosing Cholangitis (PSC) Product
 Table 75. Allergan Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 76. Allergan Recent Development
 Table 77. Shire Company Details
 Table 78. Shire Business Overview
 Table 79. Shire Primary Sclerosing Cholangitis (PSC) Product
 Table 80. Shire Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 81. Shire Recent Development
 Table 82. Durect Corporation Company Details
 Table 83. Durect Corporation Business Overview
 Table 84. Durect Corporation Primary Sclerosing Cholangitis (PSC) Product
 Table 85. Durect Corporation Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 86. Durect Corporation Recent Development
 Table 87. Conatus Pharmaceuticals Company Details
 Table 88. Conatus Pharmaceuticals Business Overview
 Table 89. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product
 Table 90. Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 91. Conatus Pharmaceuticals Recent Development
 Table 92. Sirnaomics Company Details
 Table 93. Sirnaomics Business Overview
 Table 94. Sirnaomics Primary Sclerosing Cholangitis (PSC) Product
 Table 95. Sirnaomics Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 96. Sirnaomics Recent Development
 Table 97. Shenzhen HighTide Biopharmaceutical Company Details
 Table 98. Shenzhen HighTide Biopharmaceutical Business Overview
 Table 99. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Product
 Table 100. Shenzhen HighTide Biopharmaceutical Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 101. Shenzhen HighTide Biopharmaceutical Recent Development
 Table 102. Glenmark Company Details
 Table 103. Glenmark Business Overview
 Table 104. Glenmark Primary Sclerosing Cholangitis (PSC) Product
 Table 105. Glenmark Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 106. Glenmark Recent Development
 Table 107. Impax Laboratories Company Details
 Table 108. Impax Laboratories Business Overview
 Table 109. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Product
 Table 110. Impax Laboratories Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 111. Impax Laboratories Recent Development
 Table 112. Mylan Company Details
 Table 113. Mylan Business Overview
 Table 114. Mylan Primary Sclerosing Cholangitis (PSC) Product
 Table 115. Mylan Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 116. Mylan Recent Development
 Table 117. Teva Pharmaceuticals Company Details
 Table 118. Teva Pharmaceuticals Business Overview
 Table 119. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product
 Table 120. Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 121. Teva Pharmaceuticals Recent Development
 Table 122. Daewoong Pharmaceutical Company Details
 Table 123. Daewoong Pharmaceutical Business Overview
 Table 124. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Product
 Table 125. Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 126. Daewoong Pharmaceutical Recent Development
 Table 127. Mitsubishi Tanabe Pharma Company Details
 Table 128. Mitsubishi Tanabe Pharma Business Overview
 Table 129. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Product
 Table 130. Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 131. Mitsubishi Tanabe Pharma Recent Development
 Table 132. Lannett Company Details
 Table 133. Lannett Business Overview
 Table 134. Lannett Primary Sclerosing Cholangitis (PSC) Product
 Table 135. Lannett Revenue in Primary Sclerosing Cholangitis (PSC) Business (2020-2025) & (US$ Million)
 Table 136. Lannett Recent Development
 Table 137. Research Programs/Design for This Report
 Table 138. Key Data Information from Secondary Sources
 Table 139. Key Data Information from Primary Sources
 Table 140. Authors List of This Report


List of Figures
 Figure 1. Primary Sclerosing Cholangitis (PSC) Picture
 Figure 2. Global Primary Sclerosing Cholangitis (PSC) Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Primary Sclerosing Cholangitis (PSC) Market Share by Type: 2024 VS 2031
 Figure 4. Medical Treatement Features
 Figure 5. Liver Transplantation Features
 Figure 6. Others Features
 Figure 7. Global Primary Sclerosing Cholangitis (PSC) Market Size by Application (2020-2031) & (US$ Million)
 Figure 8. Global Primary Sclerosing Cholangitis (PSC) Market Share by Application: 2024 VS 2031
 Figure 9. Hospital Case Studies
 Figure 10. Clinics Case Studies
 Figure 11. Others Case Studies
 Figure 12. Primary Sclerosing Cholangitis (PSC) Report Years Considered
 Figure 13. Global Primary Sclerosing Cholangitis (PSC) Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global Primary Sclerosing Cholangitis (PSC) Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Primary Sclerosing Cholangitis (PSC) Market Share by Region: 2024 VS 2031
 Figure 16. Global Primary Sclerosing Cholangitis (PSC) Market Share by Players in 2024
 Figure 17. Global Top Primary Sclerosing Cholangitis (PSC) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis (PSC) as of 2024)
 Figure 18. The Top 10 and 5 Players Market Share by Primary Sclerosing Cholangitis (PSC) Revenue in 2024
 Figure 19. North America Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America Primary Sclerosing Cholangitis (PSC) Market Share by Country (2020-2031)
 Figure 21. United States Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Primary Sclerosing Cholangitis (PSC) Market Share by Country (2020-2031)
 Figure 25. Germany Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Nordic Countries Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Share by Region (2020-2031)
 Figure 33. China Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Primary Sclerosing Cholangitis (PSC) Market Share by Country (2020-2031)
 Figure 41. Mexico Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Share by Country (2020-2031)
 Figure 45. Turkey Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE Primary Sclerosing Cholangitis (PSC) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Acorda Therapeutics Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 49. Gilead Sciences Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 50. NGM Biopharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 51. Intercept Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 52. Dr. Falk Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 53. Allergan Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 54. Shire Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 55. Durect Corporation Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 56. Conatus Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 57. Sirnaomics Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 58. Shenzhen HighTide Biopharmaceutical Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 59. Glenmark Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 60. Impax Laboratories Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 61. Mylan Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 62. Teva Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 63. Daewoong Pharmaceutical Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 64. Mitsubishi Tanabe Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 65. Lannett Revenue Growth Rate in Primary Sclerosing Cholangitis (PSC) Business (2020-2025)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Global Primary Sclerosing Cholangitis Treatment Market Insights Forecast to 2030
Global Primary Biliary Cholangitis Treatment Market Research Report 2024
Global Primary Biliary Cholangitis Therapeutics Market Insights Forecast to 2030
Global Bile Duct Cancer Therapeutics Market Insights Forecast to 2030
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Bile Duct Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Primary Biliary Cirrhosis Drug Market Research Report 2024
Global Cholangioscopic Direct Visualization System Market Research Report 2024
Global Biliary Tract Disorder Treatment Market Insights Forecast to 2030
Global Liver Cirrhosis Market Research Report 2024
Biliary Tract Cancers BTCs Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Liver Fibrosis Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ursodeoxycholic Acid Drug Market Research Report 2024
Global Liver Cancer Therapeutics Market Insights Forecast to 2030
Global Biliary Tumor Market Insights Forecast to 2030
Wilson s Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Compensated Cirrhosis Type C Market Research Report 2024
Global Cardiac Cirrhosis Treatment Market Research Report 2024
Biliary and Pancreatic Stents Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Nonalcoholic Steatohepatitis NASH Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Geriatric Care Services Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-17Q6174
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Hospice Software Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-8Z4276
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Geriatric Care Devices Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-8Q8325
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Allied Health Care Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29V19536
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions